Unexpected weight loss can be associated with cancer, but also with a range of other conditions

Weight loss codes in primary care typically represent 5% loss within a 6 month period, but there is a lack of evidence on how much weight loss and over what time period increase the likelihood of a cancer diagnosis in primary care

Urgently refer people over the age of 60 years with unexpected weight loss for investigations to exclude cancer

The optimal diagnostic strategy to detect cancer in patients with weight loss remains unclear

Unexpected weight loss presents a diagnostic challenge in primary care. It is associated with a wide range of benign and serious conditions (box 1).1

CardiovascularEnd stage heart failure (cardiac cachexia)

EndocrineAdrenal insufficiency, diabetes, hyperthyroidism

GastrointestinalDiarrhoea, colitis, malabsorption, mesenteric ischaemia

InfectionChronic infection (such as HIV, tuberculosis)

MalignancySolid tumours more likely than haematological malignancies

MedicationAntidepressants, antiepileptics, anxiolytics, diuretics, laxatives, stimulants

NeurologicalDementia, multiple sclerosis, neuromuscular disease, Parkinsons disease, stroke

PsychiatricAnorexia nervosa, anxiety, bulimia, depression

RenalEnd stage renal failure (uraemic cachexia)

RespiratoryChronic obstructive pulmonary disease (COPD), interstitial lung disease, vasculitis

RheumatologicRheumatoid arthritis

SocialExcess alcohol consumption, neglect, use of opiates, poor oral health, poverty, smoking

Weight loss may be missed or misattributed because of several factors (see box 2). Once it is detected, the uncertainty for clinicians is not about whether unexpected weight loss is a symptom of concern, it is about who should be investigated further and who can be spared unnecessary investigation. Specifically, how much weight loss, over how much time, in combination with what other clinical features makes cancer sufficiently likely to warrant urgent investigation?

Read this article:
When should unexpected weight loss warrant further investigation to exclude cancer? - The BMJ

Recommendation and review posted by Bethany Smith

From the age of three, Jeneen Schofields only child made the same Christmas and birthday wish: I want to be a girl.

While family snaps show the tot in a Liverpool football kit, Jeneen says her toddler, born a boy, soon sensed he should be living life as a girl.

And last year, at the age of seven, her wish came true when her name was officially changed by deed poll to Luna.

She started wearing a skirt to school and got a new passport too as one of Britains youngest transgender children.

Today her proud mum opens her heart on the life-changing events and defies critics who believe her decision to let Luna choose her gender was premature.

NHS worker Jeneen, 37, tells of the moment Luna, now eight, was set free and talks of her grieving process as she let her little boy go.

The mum says: Luna was asking when she could be a girl soon after her third birthday. I brushed it off as a phase and told her to stop being silly.

But she kept asking. My family felt she was too young to make the decision to be a girl, but I didnt want to tell her how she felt and knew this wasnt going away.

Lunas story comes as figures show the number of gender dysphoria children in Britain doubled in the past year.

Referrals to Englands only specialist clinic for transgender children have risen nearly 100 per cent in four years.

Last year 2,590 children were referred to the Leeds-based Gender Identity Development Service, where Luna visits.

Jeneen tells how Luna always shunned football stuff, preferring to play with dolls and dress-up. At five she was allowed to socially transition.

Jeneen adds: Before then shed worn princess dresses to the local shop with me, or at home. On her fifth birthday she spent the day at Disneyland Paris in a dress. She couldnt have been happier.

At the top of every Christmas and birthday wishlist was to be a girl. It was hard to accept what I was seeing.

Luna had only been at school a few weeks when Jeneen asked to speak to her teacher.

She explains: It was World Book Day. I explained Luna wanted to go as Alice in Wonderland and I asked if she thought there might be more to this. The teacher agreed, saying she noticed Luna always being the mum or sister when kids played dressing-up.

Suddenly I was so scared about how it might cause problems for her. I sat in my car and cried my heart out. I didnt really know what trans meant. For weeks I was petrified Luna would have a loveless life full of people hating her.

But Jeneen says YouTube videos of parents of trans kids talking about their situation plus resources downloaded from Mermaids, the trans-support charity helped her realise Luna could find happiness.

She adds: The more research, the more I realised transitioning didnt mean the end. Luna could have a happy life and find love as a girl.

But this month NHS psychologists said children are allowed to live as the opposite sex too soon. They say letting kids as young as six socially transition could do long-term harm by forcing them to choose too early.

Two top doctors also advised caution.

Social psychologist Dr David Canter said: No one should be assigned the label transgender before puberty. If the child is unhappy then the reasons should be explored without assigning labels.

Consultant psychiatrist and TV doc Raj Persaud added: A careful medical assessment is needed to understand what is going on. Only then can decisions be reached.

But single mum Jeneen insists it would have been wrong to let Luna live a lie. And she stresses: One thing I was sure of was how Id certainly never encouraged Luna to be a girl.

In 2016 Jeneen took Luna to Liverpool Pride, where Mermaids had a stall. They met a family with a trans child a year older than Luna.

Jeneen recalls: She had started to wear girls clothes and seemed so happy. I asked Luna if she wanted some normal girls clothes, rather than princess dresses, and she was so excited.

So she took Luna to Primark where they bought three dresses, a pair of pink jeans and some bobbles.

Seeing her spinning around in the changing rooms in her new clothes was heart-melting, like shed been set free, Jeneen says.

The moment we got home Luna emptied her wardrobe of all the boys clothes, put them into bin bags and put her new clothes up with pride.

Days later Jeneen told her mum that Luna would be wearing girls clothes.

She says: We had an explosive argument, Mum telling me, I cant take her out in girls clothes! I screamed back saying she had to be more understanding and supportive.

Mum called back later saying how sorry she was, how she loved us, but she was so scared. I explained I was more scared than anyone, but I couldnt help Luna on my own.

And with the heads blessing at the start of Lunas second year at school, she proudly wore a girls uniform.

Everyone was so accepting. Other kids would ask why she was in a dress, and shed reply, Because it makes me happy, and that was it.

The sense of relief when she came home that first day with a smile on her face was overwhelming.

Then came the issue of a name.

After trying Alice for a week, she switched to Luna a nod to the fact she and Jeneen look for the moon at night to make a wish before bedtime.

The process hasnt been easy though and Jeneen admits grieving as Facebook time hop photos would pop up of Luna as a baby making me feel like Id lost my old child.

But she stresses: I explained how I felt to friends not in the trans community. They told me I should be grateful to have a child.

Its a complex emotion as a parent of a trans child. Last thing I wanted was to cause offence to any parent who has lost a child because of an accident or illness.

After being a nurse for 11 years, Jeneen started a course in therapy and it helped her come to terms with their new life.

This, plus being part of an invaluable Mermaids network in Liverpool, gave her the confidence and strength to handle horrific online comments.

She adds: I stopped reading comments saying how the parents should be killed or needed sectioning. This was about Lunas happiness.

I know she will encounter comments as she grows up, hated for something she didnt choose, but I can either have a dead son or a happy, confident daughter.

At times, Jeneen has turned to the trans and LGBT communities, hate crime officers and even her MP for support.

A touching symbol came when Luna was re-baptised last year.

Jeneen says: The vicar couldnt have been more supportive, even wearing a rainbow silk scarf.

When I see and hear how Luna has accepted her authentic self, how happy, intelligent and hilariously funny she is, it makes me very proud. Kids need to be themselves to flourish, not what someone else wants them to be.

Luna has had five gender clinic appointments and can ask questions and explore ideas about her own identity.

Jeneen says: The next change wont be for a few years when Luna starts puberty and she can choose for herself if she wants hormone blockers and medication, and whatever else she chooses. But it will be her decision, and hers only.

Original post:
'My girl became the youngest trans toddler at just three years of age' - Mirror Online

Recommendation and review posted by Bethany Smith

he Global report entails the overall and all-encompassing study of the "Active Pharmaceutical Ingredients (API) Market" with all its relevant factors that might have an influence on the growth of the market. This report is rooted in the methodical quantitative and qualitative evaluation of the global Active Pharmaceutical Ingredients (API) market.

Click Here To Access The Sample Report:: http://www.reportsbuzz.com/request-for-sample.html?repid=51106

Furthermore, it also evaluates the most recent improvements while estimating the growth of the leading players TevaActivePharmaceuticalIndustriesLimited, DSM, Novartis, Roche, Johnson&Johnson, Dr.Reddys, Pfizer, Bayer, BASF, Cambrex, SunPharmaceuticalIndustries, Lonzagroup, BoehringerIngelheimGmbH, Aurobindopharma of the market.The key aim of this Global report is to provide updates and data relating to the Active Pharmaceutical Ingredients (API) market and also make out all the opportunities for expansion in the market. To begin with, the report entails a market synopsis and offers market definition and outline of the Active Pharmaceutical Ingredients (API) market. The synopsis section comprises market dynamics entailing market restraints, drivers, trends, and opportunities trailed by pricing analysis and value chain analysis.

The report presents a demand for individual segment in each region. It demonstrates various segments Vitamin, Antibiotics, Antipyretic&Analgesic, Hormone, AminoAcid, NervusCentralis, Others and sub-segments Hospital, Clinic, Others of the global Active Pharmaceutical Ingredients (API) market. Further, the report provides valuable data such as offerings, revenue, and a business outline of the prominent players in the Active Pharmaceutical Ingredients (API) market. The Global report draws attention to a number of avenues for the expansion of the Active Pharmaceutical Ingredients (API) market in the projected period together with its latest trends.

Read Detailed Index Of Full Research Study @:: http://www.reportsbuzz.com/51106/global-active-pharmaceutical-ingredients-api-market-outlook-2018/

In addition, the Active Pharmaceutical Ingredients (API) market is also categorized based on the types of services or product, end user, application segments, region, and others. Every segment expansion is evaluated along with the evaluation of their growth in the forecast period. Furthermore, the Active Pharmaceutical Ingredients (API) market is also divided on regional basis into the Middle East & Africa, Asia Pacific, North America, Europe, and Latin America. Lastly, the Global report on Active Pharmaceutical Ingredients (API) market offers a thorough study on industry size, sales volume, demand & supply analysis, shares, and value analysis of numerous firms along with segmental analysis, in relation to significant geographies.

There are 15 Chapters to display the Global Active Pharmaceutical Ingredients (API) market

Chapter 1, Definition, Specifications and Classification of Active Pharmaceutical Ingredients (API) , Applications of Active Pharmaceutical Ingredients (API) , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Active Pharmaceutical Ingredients (API) , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Active Pharmaceutical Ingredients (API) Segment Market Analysis (by Type);Chapter 7 and 8, The Active Pharmaceutical Ingredients (API) Segment Market Analysis (by Application) Major Manufacturers Analysis of Active Pharmaceutical Ingredients (API) ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Vitamin, Antibiotics, Antipyretic&Analgesic, Hormone, AminoAcid, NervusCentralis, Others, Market Trend by Application Hospital, Clinic, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Active Pharmaceutical Ingredients (API) ;Chapter 12, Active Pharmaceutical Ingredients (API) Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Active Pharmaceutical Ingredients (API) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.reportsbuzz.com/inquiry-for-buying.html?repid=51106

Sorry! The Author has not filled his profile.

Read more:
Global Active Pharmaceutical Ingredients (API) Market Data Analysis, Growth, Demand & Forecast 2019-2024: Teva Active Pharmaceutical Industries...

Recommendation and review posted by Bethany Smith

The global "Bone Marrow Transplant Rejection Treatment Market" report is an information bank that delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. The key points, on which the report would focus, include the production strategies incorporated by the leading market contenders, global sales growth, factors influencing and restricting the market growth, and thorough analysis by market segmentation. The global Bone Marrow Transplant Rejection Treatment market provides a giant platform for several firms, organizations, and manufacturers established across the world Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogen Inc, Boryung Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cell Source, Inc., Cell2B S.A., CellECT Bio, Inc., Cleveland BioLabs, Inc., Compugen Ltd., Cynata Therapeutics Limited, Cytodyn Inc., Dompe Farmaceutici S.p.A., Dr. Falk Pharma GmbH, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generon (Shanghai) Corporation Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Idera Pharmaceuticals, Inc. that are competing with each other in terms of offering best possible products and services to their customers and hold significant share over the market. The report provides summarized analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis.

Click Here To Access The Sample Report:: https://www.reportsbuzz.com/request-for-sample.html?repid=49789

The report presents a demand for individual segment in each region. It demonstrates various segments Azathioprine, Adrenocorticotropic Hormone, Cyclophosphamide, Cyclosporine A, Others and sub-segments Hospital, Clinic, Others of the global Bone Marrow Transplant Rejection Treatment market. The Bone Marrow Transplant Rejection Treatment market report offers a comprehensive forecast based on ongoing business techniques and trends. The Bone Marrow Transplant Rejection Treatment market report thoroughly explains minor variations in the product profile, as this variation may directly or indirectly affect the production with the appropriate description. Moreover, the global Bone Marrow Transplant Rejection Treatment market report focuses on the current and upcoming policies and regulations to be incorporated by the federal bodies, which may enhance or suppress the market growth.

Read Detailed Index Of Full Research Study @:: https://www.reportsbuzz.com/49789/global-bone-marrow-transplant-rejection-treatment-market-outlook

Apart from this, the global Bone Marrow Transplant Rejection Treatment market can be better analyzed through geographical as well as regional categorization of the market, which is also included in the report. The evaluation of the Bone Marrow Transplant Rejection Treatment market characteristics and performance depends on the qualitative as well as quantitative methods to clarify about the current position and forecast trends in the Bone Marrow Transplant Rejection Treatment market on the global basis. For making the information better understandable, the professionals and analysts have incorporated diagrams, statistical figures, flow charts, and case studies in the global Bone Marrow Transplant Rejection Treatment market report.

There are 15 Chapters to display the Global Bone Marrow Transplant Rejection Treatment market

Chapter 1, Definition, Specifications and Classification of Bone Marrow Transplant Rejection Treatment , Applications of Bone Marrow Transplant Rejection Treatment , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Bone Marrow Transplant Rejection Treatment , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Bone Marrow Transplant Rejection Treatment Segment Market Analysis (by Type);Chapter 7 and 8, The Bone Marrow Transplant Rejection Treatment Segment Market Analysis (by Application) Major Manufacturers Analysis of Bone Marrow Transplant Rejection Treatment ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Azathioprine, Adrenocorticotropic Hormone, Cyclophosphamide, Cyclosporine A, Others, Market Trend by Application Hospital, Clinic, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Bone Marrow Transplant Rejection Treatment ;Chapter 12, Bone Marrow Transplant Rejection Treatment Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Bone Marrow Transplant Rejection Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.reportsbuzz.com/inquiry-for-buying.html?repid=49789

Reasons for Buying Bone Marrow Transplant Rejection Treatment market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

See more here:
Global Bone Marrow Transplant Rejection Treatment Market Data Analysis, Growth, Demand & Forecast 2019-2024: Bellicum Pharmaceuticals, Inc. - PR...

Recommendation and review posted by Bethany Smith

Aiming to deliver thorough analysis for Global Endometriosis Market, MRD has gathered and analysed market information based on Segment1 and Segment2. It has also covered regional analysis to better understand the country wise trends and market scenario. The Global Endometriosis Market not only comprises of Key Market players and their competitive landscape, but also include the some latest trends in the healthcare sectors that are crucial for the Global Endometriosis Market, through thorough primary and secondary analysis. The list of key players includes:

Get PDF Sample Brochure of this report @ https://decisionmarketreports.com/request-sample/1204153

The list of key players includes:

AbbVieAstraZenecaBayer HealthCarePfizerAddex TherapeuticsAstellas PharmaDebiopharmElexoPharmEndoCeuticsEuroscreenForendo PharmaKissei PharmaceuticalNeurocrine BiosciencesNippon ShinyakuTakedaBayer AGNeurocrine Biosciences

Know More about this report @ https://decisionmarketreports.com/market-reports/1204153/global-coronary-artery-diesease-treatment-devices-market

The latest updates of the Global Endometriosis Market depict that the market is rapidly growing at a CAGR of xx% over the forecast period. In 2018, the Global Endometriosis Market size was close to US$ XX Million. The report also covers several chronological events such as mergers, acquisitions, product launches and new strategies adopted by companies.

Several market impact factors are affecting the Global Endometriosis Market over the forecasted period. MRD deeply analyses such factors and the direct and indirect impact triggered by such factors on the ongoing trends and future trends. The Global Endometriosis Market report encompasses all the regional trends, market drivers, challenges in the market growth, and opportunities for expansion and growth in the Global Endometriosis Market. This helps in construing the forecast figures of the Global Endometriosis Market. Additionally, the Global Endometriosis Market report is thoroughly analysed across various segments such as by product type, by application type, and by region.

Global Market Splits/Segmentation by Product Type

Gonadotropins Releasing Hormone AgonistsNon-Steroidal Anti-Inflammatory DrugsProgestinOral Contraceptive Pills

Global Market Splits/Segmentation by Applications

Hospital UseClinic UseOther

Purchase this report @ https://decisionmarketreports.com/market-reports/1204153/global-coronary-artery-diesease-treatment-devices-market/single-user/checkout

Global Market Splits/Segmentation by Region/Country North Americao U.S.o Canada Latin Americao Brazilo Argentinao Rest Europeo U.K.o Germanyo Spaino Franceo Italyo Rest of Europe Asia Pacifico Chinao Japano Indiao Australia & New Zealando ASEAN Countrieso Rest of Asia Pacific Middle East & Africao GCC Countrieso North Africao Rest of Middle East & Africa

Global Endometriosis Market USPs Market Dynamics Company Wise market Share Region wise Market Share Sales Analysis Competitor Strategy Analysis Impact Factor Analysis Adoption Rate

Table of Content

1. Executive Summary

2. Global Endometriosis Market Introduction2.1. Global Endometriosis Market Taxonomy2.2. Global Endometriosis Market Definitions2.2.1. Segment12.2.2. Segment22.2.3. Region

3. Global Endometriosis Market Dynamics3.1. Drivers3.2. Restraints3.3. Opportunities/Unmet Needs of the Market3.4. Trends3.5. New Product Launches3.6. Collaborations, Acquisitions and Mergers3.7. Growth Rates of Endometriosis Regionwise3.8. Global Endometriosis Market Competition Landscape3.9. Global Endometriosis Market Dynamic Factors Impact Analysis

4. Global Endometriosis Market Analysis, 2014 2018 and Forecast, 2019 20254.1. Market Analysis, 2014 2018 and Forecast, 2019 2025 (Revenue, USD Mn)4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)4.3. Market Opportunity AnalysisContinued

About UsDecision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

Contact UsGasper James304, S Jones Blvd,Las Vegas,NV 89107, USAUS Toll Free +18666051052Email: [emailprotected]Web: http://decisionmarketreports.com/

Here is the original post:
Global Endometriosis Market: Status and Outlook, Future Development 2019-2025 - Rapid News Network

Recommendation and review posted by Bethany Smith

Glucagon therapy is primarily used in the management of hypoglycemia in adults, children, and pregnant women. Glucagon secreted by pancreas which is released in form of glucose that raise blood glucose levels by liver to convert glycogen to glucose. Glucagon is a medication for the treatment of severe low blood sugar level (Hypoglycemia). Glucagon therapy comprises of injectable and nasal form for the treatment of hypoglycemia.

Glucagon Therapy Market: Drivers & Restraints

Glucagon therapy market is growing attributable to use as a cardiovascular stimulant after beta-blocker or calcium channel blocker overdose also glucagon therapy is utilized to restrain gastrointestinal motility to aid radiologic examinations. It may also be used to help make a detection of insulin. Increase in the number of mortality cases due to hypoglycemia, increase in the predominance of hypoglycemia in diabetic patients are the factors which contribute in the growth of glucagon therapy market. Increment in prevalence rate of hypoglycemia due to other diseases such as severe falciparum malaria have are other factors which can be responsible for the growth of glucagon therapy market. Glucagon therapy market is growing because of increment being used of beta blocker lethality as glucagon is generally accepted as an antidote, especially as first-line treatment in -blocker overdose as Cardiovascular medication overdose was the fourth driving reason of death. Increase in glucagon therapy market due to the growing prevalence of cardiovascular disease globally, trailed by an expected increase in the use of beta-blockers. Glucagon therapy is safe in pregnancy which has been approved by FDA is other factor for the growth in glucagon therapy market.

Request Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=4004

Glucagon Therapy Market: Segmentation

Glucagon therapy market has been segmented on basis of product type, application, end user and regions.

Glucagon Therapy Market can Segmentation on basis of product type

Glucagon Therapy Market can Segmentation on basis of application type

Glucagon Therapy Market can Segmentation on basis of end user

Have Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=4004

Glucagon Therapy Market: Overview

Glucagon is a hormone created in the pancreas. Glucagon is utilized to raise exceptionally low blood glucose level. Glucagon is also utilized in diagnostic testing of the stomach and other digestive organs. With the predominance of diabetes increasing worldwide at remarkable rates in late decades, the improvement of significant medication treatments have extended too. Medication for controlling blood glucose levels are accessible in various stages, and advancements in medication measurement and delivery methods appear frequently. Among the pharmaceutical formulations, injectable utilized in diabetes management is insulin, which brings down glucose levels. Glucagon, then again, increase glucose levels and is frequently utilized for the treatment of hypoglycemia. Based on product type, inject glucagon segment is expected to take largest market share of Glucagon therapy market for the forecasted period. Based on application, emergency kit segment is expected to dominate for the forecasted period. Based on end user, hospital segment is expected to dominate for the forecasted period

Glucagon Therapy Market: Regional Outlook

North America account for the largest share in the global Glucagon therapy market owing to the increase in the prevalence of hypoglycemia in diabetes patients, increase in patient inflow for hypoglycemia in an emergency department, increase in incidence rate in neonates and children, increase in patients suffering from hypoglycemia due to other diseases and launch of nasal glucagon with better clinical benefits. In addition, increasing awareness among population and regulatory approvals for the products have fueled the market development. Europe is the second largest market and holds a remarkable share in the global glucagon therapy market. The Europe glucagon treatment market is relied upon to develop fundamentally during the estimated time period owing to accessibility of cutting edge treatment facilities, skilled technical professionals, and the government support for research and advancement. Asia Pacific Image Glucagon therapy market records for the quickest developing business sector attributable to increasing prevalence of hypoglycemia with diabetes and development of new hospitals and clinic institute.

Request/View [emailprotected]https://www.factmr.com/connectus/sample?flag=T&rep_id=4004

Glucagon Therapy Market: Key Players

The key players operating in the Glucagon therapy market are Eli Lilly, Taj Pharmaceuticals, Torrent Labs, Xeris Pharmaceuticals, Novo Nordisk, Fresenius Kabi, among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Report [emailprotected]https://www.factmr.com/report/4004/glucagon-therapy-market

Link:
Glucagon Therapy Market Industry Trends and Developments 2019 2029 - SocioHerald

Recommendation and review posted by Bethany Smith

The proof-of-concept experiment showed data can be encoded in DNA and retrieved using automated systems, a development that may have positive significance for clinical laboratories

It may seem far-fetched, but computer scientists and research groups have worked for years to discover if it is possible to store data on Deoxyribonucleic acid (DNA). Now, Microsoft Research (MR) and the University of Washington (UW) have achieved just that, and the implications of their success could be far-reaching.

Clinical pathologists are increasingly performing genetic DNA sequencing in their medical laboratories to identify biomarkers for disease, help clinicians understand their patients risk for a specific disease, and track the progression of a disease. The ability to store data in DNA would take that to another level and could have an impact on diagnostic pathology. Pathologist familiar with DNA sequencing may find a whole new area of medical service open to them.

The MR/UW researchers recently demonstrated a fully automated system that encoded data into DNA and then recovered the information as digital data. In a simple proof-of-concept test, the team successfully encoded the word hello in snippets of fabricated DNA and converted it back to digital data using a fully automated end-to-end system, Microsoft stated in a news release.

The MR/UW team published their findings in Nature Scientific Reports.

DNAs Potential Storage Capacity and Why We Need It

Thus far, the challenge of using DNA for data storage hasbeen that there wasnt a way to easily code and retrieve the information. That,however, seems to be changing quite rapidly. Several major companies haveinvested heavily in research, with consumer offerings expected soon.

At Microsoft Research, consumer interest in genetic testing has driven the research into using DNA for data storage. As People get better access to their own DNA, why not also give them the ability to read any kind of data written in DNA? asked Doug Carmean, an Architect at Microsoft, during an interview with Wired.

Scientists are interested in using DNA for data storage becausehumanity is creating more data than ever before, and the pace is accelerating.Currently, most of that data is stored on tape, which is inexpensive, but hasdrawbacks. Tape degrades and has to be replaced every 10 years or so. But DNA,on the other hand, lasts for thousands of years!

DNA wont degrade over time like cassette tapes and CDs, and it wont become obsolete, Yaniv Erlich, PhD, Chief Science Officer at MyHeritage, an online genealogy platform located in Israel, and Associate Professor, Columbia University, told Science Mag.

Tape also takes up an enormous amount of physical space compared to DNA. One single gram of DNA can hold 215 petabytes (roughly one zettabyte) of data. Wired puts the storage capacity of DNA into perspective: Imagine formatting every movie ever made into DNA; it would be smaller than the size of a sugar cube. And it would last for 10,000 years.

Victor Zhirnov, Chief Scientist at Semiconductor Research Corporation says the worries over storage space arent simply theoretical. Todays technology is already close to the physical limits of scaling, he told Wired, which stated, Five years ago humans had produced 4.4 zettabytes of data; thats set to explode to 160 zettabytes (each year!) by 2025. Current infrastructure can handle only a fraction of the coming data deluge, which is expected to consume all the worlds microchip-grade silicon by 2040.

MIT Technology Review agrees, stating, Humanity is creating information at an unprecedented ratesome 16 zettabytes every year. And this rate is increasing. Last year, the research group IDC calculated that well be producing over 160 zettabytes every year by 2025.

Heavy Investment by Major Players

The whole concept may seem like something out of a sciencefiction story, but the fact that businesses are investing real dollars into itis evidence that DNA for data storage will likely be a reality in the nearfuture. Currently, there are a couple of barriers, but work is commencing toovercome them.

First, the cost of synthesizing DNA in a medical laboratoryfor the specific purpose of data storage must be cheaper for the solution tobecome viable. Second, the sequencing process to read the information must alsobecome less expensive. And third is the problem of how to extract the datastored in the DNA.

In a paper published in ASPLOS 16, the MR/UW scientists wrote: Today, neither the performance nor the cost of DNA synthesis and sequencing is viable for data storage purposes. However, they have historically seen exponential improvements. Their cost reductions and throughput improvements have been compared to Moores Law in Carlsons Curves Important biotechnology applications such as genomics and the development of smart drugs are expected to continue driving these improvements, eventually making data storage a viable application.

Automation appears to be the final piece of the puzzle. Currently,too much human labor is necessary for DNA to be used efficiently as datastorage.

It may take some time before DNA becomes a viable medium fordata storage. However, savvy pathology laboratory managers should be aware of,and possibly prepared for, this coming opportunity.

While its unlikely the average consumer will see muchdifference in how they save and retrieve data, medical laboratories with theability to sequence DNA may find themselves very much in demand because oftheir expertise in sequencing DNA and interpreting gene sequences.

Dava Stewart

Related Information:

With a Hello, Microsoft and UW Demonstrate First Fully Automated DNA Data Storage

Demonstration of End-to-End Automation of DNA Data Storage

UW Team Stores Digital Images in DNAand Retrieves Them Perfectly

Microsoft and UW Demonstrate First Fully Automated DNA Data Storage

Storing Data in DNA Is A Lot Easier than Getting It Back Out

DNA Could Store All of the Worlds Data in One Room

The Rise of DNA Data Storage

Forget SiliconSQL On DNA Is the Next Frontier for Databases

View original post here:
Microsoft Research Develops DNA Storage - DARKDaily.com - Laboratory News

Recommendation and review posted by Bethany Smith

Prostate cancer grows so slowly in some men that doctors often recommend active surveillance or watchful waiting instead of more aggressive treatment. In fact, one study from the Johns Hopkins Active Surveillance Program found that less than 1% of men with low-risk prostate cancer developed metastatic disease after 15 years of active surveillance.

But if prostate cancer grows slowly, the same cant be said for research into the disease.

In fiscal year 2017 alone, the National Cancer Institute (part of the National Institutes of Health) funded 876 studies into prostate cancer, while the Prostate Cancer Foundation reports that nearly 1,000 clinical trials are exploring treatments and treatment strategies in the U.S. Some of that research will lead to improvements in prevention, detection and treatment. In fact, prostate cancer deaths have been cut in half since 1993, when the Prostate Cancer Foundation was founded. The five-year survival rate now stands at 99%.

Yet prostate cancer is still the second-deadliest cancer among American men (after lung cancer). Theres a misperception that this is a disease of old men that no one dies of, says Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation. Thats wrong; a man still dies every twenty-one minutes around the clock from prostate cancer.

Since September is National Prostate Cancer Awareness Month, this is a great time to review recent developments in prevention, diagnosis and treatment.

Prostate cancer occurs when cells in the prostate, a small gland below the bladder involved in the production of sperm, begin to grow abnormally.

The first sign of the disease is often an elevated prostate-specific antigen (PSA) count in a blood test. Diagnosis and staging are confirmed through a digital rectal exam (DRE) and tissue biopsies, while genetic testing can help determine the cancers aggressiveness, an important factor in weighing treatment options.

A man still dies every twenty-one minutes around the clock from prostate cancer.

Those options include active surveillance, surgery, chemotherapy, radiation therapy and hormone therapy, each of which comes with its own set of risks and benefits. For example, surgery and radiation can affect urinary, bowel and sexual function, which is one reason active surveillance is preferable for slow-growing, localized prostate cancer.

Until recently, doctors assumed that the key risk factors for prostate cancer were age, a family history of prostate cancer and being of African-American ancestry. Today, however, researchers like Dr. Heather Cheng are looking at family history more broadly.

An associate professor of medical oncology at the University of Washington School of Medicine, Cheng says there are proven genetic links between prostate cancer in men and breast, ovarian and pancreatic cancer in their female relatives.

If there is an inherited cancer risk, that risk may manifest itself in female relatives differently than in male relatives, Cheng says.

The genetic links work both ways. When sharing their family history with their doctors, men should include information about female relatives on both sides of the family who have had cancer. And men who are diagnosed with metastatic prostate cancer should undergo genetic testing, as should their siblings and children if a mutation is discovered.

That doesnt mean a person will definitely get cancer, but it may increase their risk, Cheng says. It also provides information for them to use that risk knowledge to be proactive.

Family history can also help inform a patients decision about whether to have a PSA test. That test is no longer routinely recommended due to the potential for overtreatment, but Cheng says it becomes more important if a man has a known mutation or if theres a family history of early breast and ovarian cancer.

The most inherited cancer of a hundred and eighty seven human cancers is, in fact, prostate cancer; thats been discovered in the last two years, says Jonathan Simons of the Prostate Cancer Foundation. Whats kind of radical is that every urologist should be a genetic counselor.

While an apple a day wont necessarily keep the doctor away, eating tomatoes, guava, watermelon, pink grapefruit, tree nuts, eggplant, spinach and beets may well keep prostate cancer at bay, according to Dr. William W. Li., author of Eat to Beat Disease: The New Science of How Your Body Can Heal Itself.

Numerous studies have shown that certain foods contain natural chemicals that inhibit tumor angiogenesis (the growth of new blood vessels), Li explains. This means eating those foods can starve the cancer by cutting off the tumor blood supply. For example, a National Cancer Institute study of nearly 50,000 men found that those who ate more cooked tomatoes, which are rich in lycopene, had a 28% lower risk of developing prostate cancer.

In fact, Prostate cancer is the most sensitive cancer to a change in diet in terms of surviving longer, says Simons.

Exercise even brisk walking plays a role as well. Exercise improves immunity, which is important for preventing cancer, Li says. It also helps the body fight tumor angiogenesis, which can prevent or slow cancer growth. Exercise also improves the cardiovascular system, brain function and muscle strength all important factors for healthy aging.

The Prostate Cancer Foundation estimates that 175,000 men in the United States will be diagnosed with prostate cancer this year. Fortunately, recent advances are making it easier to detect and treat the disease, according to Dr. Sven Wenske, who practices urology at the Columbia University Irving Medical Center in New York City.

One important advance is the development of magnetic resonance imaging (MRI) fusion technology, in which MRI and ultrasound images are combined to give physicians a better picture of the prostate.

Instead of just taking random (biopsy) samples under ultrasound guidance only from the left and the right lobe (parts of the prostate), we basically target specific areas that the MRI shows us to be abnormal, Wenske says. This is a much more specific and much more accurate way to diagnose prostate cancer. Whats more, the technology can also be used during active surveillance to determine the need for additional biopsies.

In cases of metastatic prostate cancer, doctors now have more tools in their toolboxes, thanks to second-generation anti-androgens. Androgens are male hormones including testosterone, which helps cancer grow. The new anti-androgens include apalutamide, enzalutamide and darolutamide, the latter of which was approved by the Food and Drug Administration in July 2019.

These drugs really help to keep the cancer under control, Wenske says.

More drug approvals are on the horizon. In fact, Simons recommends patients keep up with the latest news on the Prostate Cancer Foundations website because some clinicians may not be aware of the latest developments.

Also on the horizon are increasingly targeted therapies that are no undergoing clinical trials. For example, researchers are testing radioactive molecules that can move through the bloodstream, searching for and destroying prostate cancer cells. These agents target prostate membrane-specific antigen, or PSMA, a protein on the surface of the cells.

Genetics may play a role here as well; a study from The Institute of Cancer Research has shown that genetic testing could help identify patients who would respond well to this therapy.

Although much of the recent news about treatments for prostate cancer has been positive, a study published in July 2019 offered a stark reminder that standard treatments can have serious side effects.

Researchers at the University of Pennsylvanias Perelman School of Medicine did a retrospective study of 154,000 prostate cancer patients and found that androgen-deprivation therapy (ADT; also called hormone therapy) was associated with a heightened risk of developing dementia and Alzheimers disease. Specifically, 13% of patients who received ADT developed Alzheimers disease, compared with 9% of patients who didnt receive the therapy, while 22% of ADT patients developed some form of dementia, versus 16% of non-ADT patients.

Those results didnt surprise Wenske, who has seen anecdotal evidence among his own patients. Unfortunately, he says, thats the only way at this time to really suppress the cancer. If they dont do that treatment, they have a risk for progression. Theres not a lot of wiggle room between choices.

Thats why its reassuring that the National Cancer Institute, the Prostate Cancer Foundation and other groups continue pouring money into research and clinical trials. Perhaps one day, negative side effects and prostate cancer itself will become distant memories.

The Prostate Cancer Foundation offers several free resources on its website, including the Prostate Cancer Patient Guide (updated for 2019) and The Science of Living Well, Beyond Cancer (published in August 2019), which explores the relationship between lifestyle choices and cancer.

Next Avenue brings you stories that are inspiring and change lives. We know that because we hear it from our readers every single day. One reader says,

"Every time I read a post, I feel like I'm able to take a single, clear lesson away from it, which is why I think it's so great."

Your generous donation will help us continue to bring you the information you care about. What story will you help make possible?

Next Avenue - 2019. All rights reserved.

Read the original:
The Latest in Prostate Cancer Treatment - Next Avenue

Recommendation and review posted by Bethany Smith

The Preimplantation Genetic Testing Market Introduction

Preimplantation genetic testing is the process which is used prior to implantation to help identify genetic defects within embryos. This process helps to prevent certain genetic disorders that can transfer from parents to child. It involves screening single cells from embryos and performed during the process of in-vitro fertilization (IVF) prior to embryo transfer. Two main procedures are done for preimplantation genetic testing: preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). The main application of PGD is to identify the presence of chromosomal translocations and single-gene disorders so that these embryos are not transferred and a healthy, disease free babys birth can take place. This process is also done to determine the sex of the embryo prior to the transfer into the uterus. Different techniques are used in preimplantation genetic testing such as Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Fluorescence in Situ Hybridization (FISH) for detection of disorders.

Preimplantation genetic screening (PGS) is applied technology from PGD and generally done for those people with recurrent pregnancy loss or infertility. Embryos are screened to determine the cause of miscarriage and implantation failure. Through this screening, abnormal embryos are identified so they are not transferred to the IVF cycle, to achieve successful pregnancy. PGS is done to screen an embryo for normal chromosome number or to identify loss or gain of chromosomal material.

Stuck in a Neck-to-Neck Competition with Other Brands? Request a Custom Report on Preimplantation Genetic Testing Market here

Preimplantation Genetic Testing Market Competitive Landscape

The global preimplantation genetic testing market is fragmented due to presence of major players. Key players operating in the global preimplantation genetic testing market include Agilent Technologies, Inc., Illumina, Inc., Abbott Laboratories, CooperSurgical, Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., Natera, Inc., Quest Diagnostics Incorporated, Genea Limited, and Vitrolife.

New product launch, partnerships, collaborations, and mergers & acquisitions are some of the key strategies adopted by these major players in developed as well as emerging economies. For instance, in January 2017, Agilent Technologies, Inc. and the Centre for Human Genetics, University of Leuven, and University Hospitals Leuven collaborated to investigate new solutions of preimplantation genetic testing.

Agilent Technologies, Inc.

Agilent Technologies, Inc. is headquartered in Santa Clara, CA, U.S. and operates in life sciences, diagnostics, and applied chemicals markets. The company was founded in 1999 and offers instruments, services, consumables, applications, and expertise to address the full range of scientific and laboratory management needs. Agilent Technologies, Inc. provides OnePGT Solution for research purposes which uses NGS technology.

Illumina, Inc.

Founded in 1998, Illumina, Inc.is based in San Diego, California, U.S. The company develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It has a global presence with over 7,300 employees globally. Illumina, Inc. offers various karyomapping products and solutions for PGD such as Infinium HumanKaryomap-12 DNA Analysis Kit and NextSeq 550 System.

The company has adopted a distribution partnership, collaboration, and alliances strategy for its PGD products. For instance, in October 2018, Illumina, Inc. and Vitrolife signed a distribution agreement. This agreement provided exclusive development, distribution, and commercialization rights to Vitrolife for Illumina, Incs. Preimplantation genetic testing business for IVF in the Americas and EMEA.

Abbott Laboratories

Established in 1888, Abbott Laboratories is headquartered in Chicago, Illinois, U.S. Abbott Laboratories is a major healthcare company which offers healthcare products and solutions such as diagnostics, medical devices, nutritionals, and branded generic medicines. The company serves more than 160 countries. Its PGD products and solutions comes under the genetics and genomics product division.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/preimplantation-genetic-testing-market.html

CooperSurgical, Inc.

Founded in 1990, CooperSurgical, Inc. is based in Trumbull, Connecticut, U.S. The company has a diversified product portfolio of more than 600 products. It operates through two business segments: CooperSurgical medical devices and CooperSurgical Fertility & genomic solutions. The company offers PGT-A, PGT-M, and PGT-SR, which are major test solutions for PGD and PGS.

Preimplantation Genetic Testing Market- Dynamics

Rise in number of cases of child birth with genetic disorders and declining fertility rate globally to drive the global preimplantation genetic testing market

Increasing incidence of child birth with genetic disorders such as cystic fibrosis, Huntingtons disease, Down syndrome, and Turner syndrome due to chromosomal abnormalities, single gene defects, and other reasons is being seen. Rise in conditions of genetic disorders & abnormalities is attributed to growth of global preimplantation genetic testing market. For instance, as per CDC, around 6,000 babies are born with Down syndrome in the U.S. every year. According to the same report, between1979 to 2003, and the number of babies born with Down syndrome increased by about 30% in the U.S. Moreover, fertility rate among the current population is declining in recent years due to lifestyle changes which is propelling the need for PGS and hence the preimplantation genetic testing market is slated to grow globally.

Need an Overview of the Report on Preimplantation Genetic Testing Market? Ask for the Brochure here

Higher risk of chromosomal abnormalities associated with advancing maternal age and more IVF procedures coupled with rise in number of fertility clinics, major growth drivers of the market

The risk of chromosomal abnormality increases with maternal age. A baby born to an older woman has higher risk of being born with some type of chromosomal abnormality & defect. According to an article published by Stanford Children's Health, U.S., the chance of having a child affected by Down syndrome rises from around 1 in 1,250 for a woman who conceives at the age of 25 years, to about 1 in 100 for a woman who conceives at the age of 40 years. Also, rise in number of fertility clinics and IVF procedures worldwide is propelling the growth of the global preimplantation genetic testing market.

Higher procedural cost and certain regulatory norms restraining the market growth

Factors such as higher cost associated with PGD & PGS and certain strict regulatory norms are likely to hamper the growth of the global preimplantation genetic testing market. Preimplantation genetic testing is a complex procedure that entails a lot of laboratory work; hence, the cost can be significant and high for the entire procedure. Also, non-medical use of PGD and PGS raises the government regulatory norms in certain countries. These strict rules are likely to hamper the growth of the global preimplantation genetic testing market.

North America preimplantation genetic testing Market Major Market

North America dominated the global preimplantation genetic testing market in 2018. It is projected to maintain its position during the forecast period. Higher infertility rate, more number of IVF cycles, presence of major players in the region, and adoption of highly advanced technologies for genomics are some of the major factors responsible for the dominance of this region in the global market. For instance, according to CDC data, between 2011 to 2015, 6.7% of married women aged 15-44 years were facing infertility problems in the U.S.

Preimplantation Genetic Testing Market Segmentation

The global market can be segmented on the basis of: Procedure Type Product & services Technology Application End-user Region

Preimplantation Genetic Testing Market Segmentation By Procedure Type

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=70167&source=atm

Based on procedure type, the market can be segmented into: Preimplantation Genetic Diagnosis Preimplantation Genetic Screening

Preimplantation Genetic Testing Market Segmentation By Product & Services

In terms of product & services, the market can be divided into: Reagents & Consumables Instruments Softwares & Services

Preimplantation Genetic Testing Market Segmentation By Technology

On the basis of technology, the market can be classified into: Polymerase Chain Reaction(PCR) Next-Generation Sequencing(NGS) Fluorescence in Situ Hybridization(FISH) Others

Preimplantation Genetic Testing Market Segmentation By Application

Depending on application, the market can be segmented into: Aneuploidy Single Gene Disorders Structural Chromosomal Abnormalities Gender Identification HLA Typing Others

Structural Chromosomal Abnormalities segment is further sub segmented into- Inversions Translocations Deletions Duplications

Preimplantation Genetic Testing Market Segmentation By End-user

Based on end-user, the market can be divided into: Hospitals, Diagnostic Labs & Service Providers Maternity & Fertility Centers Research Laboratories & Academic Institutes

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=70167&source=atm

Link:
Preimplantation Genetic Testing Market Opportunity Analysis and Industry Forecast up to 2027 - Rapid News Network

Recommendation and review posted by Bethany Smith

A recent Peer Exchange series from The American Journal of Managed Care brought together a panel of experts to discuss spinal muscular atrophy (SMA), including its clinical presentation, diagnosis of its various types, and the potential of new disease-modifying treatments. The panel was moderated by Peter L. Salgo, MD.

SMA is not a common disease, and Salgo admitted he was unaware of it until he began preparing to moderate the series, but it is actually the most common genetic cause of infant death, according to John Brandsema, MD.1 This neurodegenerative disorder most commonly presents in infants with symptoms of limb weakness. In the most severe form of the disease, SMA type 1, which has the earliest onset, symptoms include impaired respiratory function.

The most common thing would be in an infant, hypotonia and a little bit of floppiness, which can be part of normal spectrum of development in some kids. Most primary specialists might think of something like instituting some physical therapy for a couple of months and seeing whether that helps the patient, Brandsema explained. But in SMA type 1, that is an eternity because theyre going to get worse during that time and start to show problems with their breathing and their feeding.1

To confirm suspected SMA, clinicians perform genetic testing to search for double deletion of the SMN1 gene, which causes the SMN protein deficiency that leads to the symptoms of motor neuron loss and weakness.2

The type of diagnostic scale used to assess the severity of SMA depends on a patients age, Brandsema said.2 Young infants with type 1 SMA will often undergo the Childrens Hospital of Philadelphia Infant Test of Neuromuscular Disorders and the Hammersmith Infant Neurological Exam, whereas slightly older patients with type 2 or type 3 disease would be measured with the Hammersmith Functional Motor Scale.

Youre really trying to find the right test thats going to measure the patients function in the moment and also how theyre changingwhich, in the natural history, would be loss over time on these scales of points or function, Brandsema said. But with these new disease-modifying therapies, it may in fact be improvement.2

The new targeted gene therapies that Brandsema referenced have produced significant therapeutic impact and changed the landscape of SMA treatment, but insurance coverage can determine patients access. Payers are not sure how long the benefits of treatment will last, which makes it difficult for them to determine the value of these treatments, according to Surya Singh, MD.

People usually think about longevity in terms of the patient, Singh explained. But here, as were just about on the cusp of sort of viral delivered gene therapythe question becomes, does this method for producing the protein that we want continue to work? Or does the body find some way to be able to decrease those levels? And what happens then? Does it require a boost?3

Although these questions have yet to be answered, the panelists agreed that the therapeutic developments have given hope to families who previously had none.

Im excited, and I am proud to be in a profession that has done this for people and is continuing to do this for peopleand that includes insurance, Salgo concluded. Everybody has got a piece of this, and its all going the right way.4

References

1. Spinal muscular atrophy (SMA) and types of SMA. The American Journal of Managed Care website. ajmc.com/peer-exchange/rare-neurological-diseases/spinal-muscular-atrophy-sma-and-types-of-sma. Published July 8, 2019. Accessed August 20, 2019.

2. Diagnostic tests and scales of SMA. The American Journal of Managed Care website. ajmc.com/peer-exchange/rare-neurological-diseases/diagnostic-tests-and-scales-of-sma. Published July 22, 2019. Accessed August 20, 2019.

3. Payer perspective and value of treatment of SMA. The American Journal of Managed Care website. ajmc.com/peer-exchange/rare-neurological-diseases/segment-title-payer-perspective-and-value-of-treatment-of-sma. Published August 12, 2019. Accessed August 20, 2019.

4. Risdiplam and final thoughts. The American Journal of Managed Care website. ajmc.com/peer-exchange/rare-neurological-diseases/risdiplam-and-final-thoughts. Published August 19, 2019. Accessed August 20, 2019.

See more here:
Experts Discuss Symptoms, Types, and Treatments of SMA - AJMC.com Managed Markets Network

Recommendation and review posted by Bethany Smith

The latest research report byvertexmarketinsights.comAnd Consulting on Breast Cancer Predictive Genetic Testing gives complete guidance which provides the most recent Breast Cancer Predictive Genetic Testing industry patterns like marketdevelopment openings, growth, size, and share. Global Breast Cancer Predictive Genetic Testing Market report includes an introduction to new trends that can guide the organizations performing in theindustry to comprehend the market and increase the procedures for their business development individually.

This report additionally introduces item particular, fabricating procedure, and item cost structure and so forth. Creation is separated by locales, technology and applications. Other important aspects that have been meticulously studied in the Breast Cancer Predictive Genetic Testing market report is: Request and supply elements, import and export situation, industry procedures and cost structures. At the end, the report includes Breast Cancer Predictive Genetic Testing new project SWOT analysis, investment feasibility analysis, investment return examination, and advancement pattern investigation.

Request For Free Sample Copy @: https://www.vertexmarketinsights.com/report/13489/global-breast-cancer-predictive-genetic-testing-market-research-report-2019-by-manufacturers-regions-types-and-applications/#request-sample

Top Key players of Global Breast Cancer Predictive Genetic Testing Market:

RocheThermo Fisher ScientificPerkinElmerQuest DiagnosticsMyriad GeneticsIverson GeneticsCancer GeneticsOncoCyte CorporationNeoGenomicsInvitae

Scope Of the report:

Based on different characteristics of Breast Cancer Predictive Genetic Testing , the market is divided into the segment. This division will assist advertisers with personalizing your market campaigns and furthermore decreases the danger of unbeneficial market campaigns. Through this division, you can without much of a stretch recognize your intended interest group.

Breast Cancer Predictive Genetic Testing report offers:

* Strategic recommendations for the new entrants.

* Market share assessments for the regional and country level segments.

* Competitive landscaping mapping the key common trends.

* Supply chain trends mapping the latest technological advancements.

* Strategic recommendations in key business segments based on the market estimations.

* Company profiling with detailed strategies, financials, and recent developments.

* Market Trends (Drivers, Challenges, Constraints, Threats, Investment Opportunities, and recommendations).

Below Table contains Types & Applications of Breast Cancer Predictive Genetic Testing Report

If you have any Query Ask to Our Support Team @ https://www.vertexmarketinsights.com/report/13489/global-breast-cancer-predictive-genetic-testing-market-research-report-2019-by-manufacturers-regions-types-and-applications/#inquiry-before-buying

There are 15 Chapters to display the Global Breast Cancer Predictive Genetic Testing Systems market

Chapter 1, Definition, Specifications and Classification of Breast Cancer Predictive Genetic Testing Systems , Applications of Breast Cancer Predictive Genetic Testing Systems , Market Segment by Regions;

Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, Technical Data and Production Plants Analysis of Breast Cancer Predictive Genetic Testing Systems , Capacity and Commercial Manufacturing Date, Production Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);

Chapter 5 and 6, Local Market Analysis that involved United States, China, Europe, Japan, Korea & Taiwan, Breast Cancer Predictive Genetic Testing Systems Segment Market Analysis (by Type);

Chapter 7 and 8, The Breast Cancer Predictive Genetic Testing Systems Segment Market Analysis (by Application) Major Manufacturers Analysis of Breast Cancer Predictive Genetic Testing Systems ;

Chapter 9, Market Trend by Product Type Hybrid System, Electric Power Propulsion Systems, Steam Turbines Propulsion Systems, Diesel Propulsion Systems, Market Trend by Application Ocean-going Ships, Commercial Vessels, Pleasure Craft, Military Vessels;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, The Consumers Analysis of Global Breast Cancer Predictive Genetic Testing Systems ;

Chapter 12, Breast Cancer Predictive Genetic Testing Systems Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, Breast Cancer Predictive Genetic Testing Systems sales channel, distributors, traders, sellers, Research Findings and Conclusion, appendix and information source.

Explore Detailed Report @: https://www.vertexmarketinsights.com/report/13489/global-breast-cancer-predictive-genetic-testing-market-research-report-2019-by-manufacturers-regions-types-and-applications/#table-of-contents

More:
Global Breast Cancer Predictive Genetic Testing Market Size and CAGR Forecast by Type, Application, Region (2019-2024) - SocioHerald

Recommendation and review posted by Bethany Smith

By George Lorenzo, Next Avenue Contributor

Getty

The progression and symptoms of early-onset Alzheimer's Disease, typically identified in patients in their 40s or 50s, can vary dramatically depending on the individual. According to the Alzheimers Association, getting an accurate diagnosis of early-onset Alzheimer's can be a long and frustrating process. Symptoms may be incorrectly attributed to stress or there may be conflicting diagnoses from different health care professionals.

The Alzheimers Drug Discovery Foundation (ADDF) is working to eliminate such conflicts through its $50 million Diagnostics Accelerator program. It's aimed at supporting the development of novel biomarkers" for the early detection of Alzheimer's and related dementias.

We want to accelerate the science, says Dr. Howard Fillit, founding executive director and chief science officer of ADDF. That means providing funding to support innovative research to quicken the process of developing and implementing clinical trials required for regulatory approval of Alzheimer's diagnostic tools and programs.

The onset of Alzheimer's, in general, is currently diagnosed through: mental and neuropsychological tests performed by primary care doctors and/or neurologists, along with a review of a patients medical history; genetic testing that identifies the APOE e4 gene associated with early-onset Alzheimer's; a PET scan or invasive spinal tap that may reveal the presence of amyloid plaques and/or tau tangles in the brain and a CT or MRI that can identify vascular dementia.

Also on Forbes:

All of these solutions are relatively expensive (excluding mental testing), time-consuming, challenging to take advantage of, and, in some cases, not administered properly nor proven to yield 100% valid results in diagnosing Alzheimer's.

We must now develop inexpensive and noninvasive biomarkers, preferably blood tests, that will help diagnose Alzheimers disease and track the effectiveness of treatments, wrote Fillit in a recent article published in Scientific American.

DDFs first round of award recipients, announced on May 30, 2019, allocated approximately $3.5 million to two Alzheimer's diagnosis blood tests and two retinal imaging R & D programs. The four Saliha Mussaoui, Amoneta Diagnostics, based in France; Kaj Blennow, University of Gothenberg, Sweden; Tom MacGillivray, University of Edinburgh, Scotland andPeter van Wijngaarden, the Centre for Eye Research in Australia were chosen out of 300 applicants from 30 countries.

Creating a Blood Test to Identify Early-Onset Alzheimer's

Amoneta is an affiliate of Firalis, a life sciences biotechnology company created by Dr. Huseyin Firat. Since 2014, Amoneta has conducted research and development for ultimately creating a valid blood test that can identify mild cognitive impairment (MCI) and early-onset Alzheimer's.

The test, called MemoryLINC, is based on finding difficult-to-monitor and characterize lncRNAs (long noncoding ribonucleic acids) in blood panels. These lncRNAs regulate gene expression and diverse biological functions. It is increasingly recognized that lncRNAs is tightly related to the pathogenesis and prevention and cure of AD (Alzheimer's Disease), notes a January 2019 study published in Pathology - Research & Practice.

Fillit says Amoneta has data indicating that certain RNAs are elevated in blood samples of people with Alzheimer's that are relevant to learning and memory and the disease itself.

The MemoryLINC Project has reached its final clinical validation phase comprised of 800 subjects at 13 European clinical sites in France, Switzerland, Belgium and Turkey. Firat says the MemoryLINC study is the most important clinical study ever done in this domain.

Tau-related Research

The ADDF funding for Blennows project intends to develop brain-specific, tau-related blood tests to identify and monitor neurodegeneration. Tau is a protein contained in nerve cells. It resides in cerebrospinal fluid in the brain and spinal cord and can be gauged through an invasive and highly uncomfortable spinal tap.The aggregation and collapse of tau into tangles that elevate and spread throughout the brain is symptomatic of Alzheimer's.

Measuring tau in blood can be very useful, Fillit explains. But the problem is that tau is present in the blood in such low quantities as it relates to [Alzheimer's] that, so far, we havent been able to measure it effectively. Blennow, however, has discovered how to measure brain-specific tau fragments in blood.

Over the next two years, Blennows team will evaluate the presence of different levels of tau in blood samples. Many of these samples will be identified from a Swedish BioFINDER cohort at Lund University, which includes 600 cognitively healthy individuals, 500 patients with subjective cognitive dysfunction or mild cognitive impairment, and 100 patients with Alzheimer's.

This is an exploratory project aiming to develop a novel analytical method to establish robust blood biomarkers for tau, Blennow explains.

The other two ADDF-funded awardees are conducting research on imaging techniques and processes that can identify the possible unhealthy accumulation of amyloid plaques behind the retina, which is another symptom of Alzheimer's. The Alzheimers Associations 2019 Alzheimers Disease Facts and Figures report noted that recent research has shown that the accumulation of amyloid in the brain were significantly increased starting 22 years before symptoms were expected to develop.

In addition to focusing on amyloid buildup, MacGillivrays project is looking closely at vascular changes in the small blood vessels in the back of the retina, both of which can be seen with Optical Coherence Tomography (OCT) machines that are commonly utilized by ophthalmologists.

MacGillivray says the health of small blood vessels is an increasingly recognized component of dementia and Alzheimer's. We think we see differences in how wide or how narrow these blood vessels are, and also the number of blood vessels that fill the tissue space," he notes.

We are seeing potentially a dying lack of blood vessels or a less optimum range of blood vessels delivering oxygen and nutrients to vascular tissue, and this is then replicated in the brain," says MacGillivray. "We have a quick and non-invasive way to see if blood vessels are changing [by utilizing relatively inexpensive OCT imagery scans] and degrading in a detrimental way inside the brain without having to go through expensive techniques such as MRIs and PETS.

Imagine a world where people who may have memory problems are referred by their primary care doctor to the ophthalmologist around the corner, Fillit says. The ophthalmologist uses the OCT machine to see if there is an amyloid plaque buildup in the back of the eye. It could tell you whether a person is "cooking" Alzheimer's or not, notes Fillit.

These same principles apply to Wijngaardens project, but with different mechanisms and equipment. This one also deals with looking behind the retina for amyloid plaques, but utilizes a sophisticated camera technology, called hyperspectral imaging. That technology can capture images behind the retina revealing different colors of light that correlate to early-onset Alzheimer's based on amyloid plaque buildup.

We can get a wealth of information about the structure of the back of the eye, Wijngaarden says.

To support his research and ultimately incorporate it into everyday clinical practice, Wijngaarden has developed a low-cost portable camera for hyperspectral imaging of the retina. It's being tested for use in routine eye exams where the camera will identify amyloid plaque buildup years before a patient might show signs of cognitive decline.

The Future

What we want to do with the digital accelerator is advance these technologies, measuring things like function, cognition and a whole variety of other variables, Fillit says.

How long will it take for such innovative technologies to possibly get government approval through clinical trials and validation and ultimately reach patients at their next doctor visit? Amoneta estimates that its blood test could be launched for use in clinics in the U.S. and Europe by 2021. The three other awardees all agree that it should take three to five years for their technologies to possibly become common practice in clinics.

Go here to see the original:
Detecting Early Onset Alzheimers Disease In Innovative Ways - Forbes

Recommendation and review posted by Bethany Smith

Sep 21, 2019 10:17 AM EDT

In the body's cells, some proteins are of vital importance as to which genes are active or turned off. Now, researchers from the University of Copenhagen and the Memorial Sloan Kettering Cancer Center have discovered which proteins are necessary in order to maintain the proper genetic regulation.

All of the more than 200 different cell types in our body contain the same DNA. Which of those genes that are expressed determine each cell type. Therefore, it is essential that the activity of the genes is controlled with great precision.

Thus, a stem cell may develop into anything from skin to a bone cell, depending on which parts of the genome that are expressed.

The researchers in Professor Kristian Helin's research group have for several years worked to understand the mechanisms that control whether a gene is active or inactive. This research is crucial to the understanding of how cells become specialized and maintain their identity, the normal embryonic development, and how various diseases may develop.

In a new study, researchers working at the Biotech Research & Innovation Center (BRIC) and the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen as well as the Memorial Sloan Kettering Cancer Center in New York have achieved crucial new results.

The results were recently published in the scientific journal Molecular Cell and provide insight into the ways in which epigenetic mechanisms control the activity of genes.

'In addition, the results may have an impact on the future treatment of certain cancers related to the studied protein complex, including lymphoma, leukemia and a special type of brain cancer that is often seen in children', says Kristian Helin, Professor at BRIC and Director of Research at the Memorial Sloan Kettering Cancer Center.

Turning On and Off

One of the key protein complexes that regulate whether genes are turned on or off is called PRC2. To ensure that the complex binds to the right places in the genome, a number of other proteins are associated with PRC2.

In the recently published article, the research group has studied the importance of six different proteins associated with PRC2, and the group has shown that all six proteins help direct PRC2 to the right places in the genome.

In 15 different combinations, the researchers removed the associated proteins from embryonic stem cells one by one. In this way, the researchers were able to study the contribution of each protein to the activity and binding of the PRC2 complex to specific areas. It was found that the ability to find the way to the right places in the genome remained intact until all six associated proteins were removed from the stem cells.

That finding surprised the researchers, says the study's lead author, Postdoc Jonas Hjfeldt:

'We assumed that each of the associated proteins was responsible for its own area to where the PRC2 complex should be guided. Instead, we saw that they all contributed to the places where the complex binds. As long as just one of the associated proteins were left, the ability remained intact', he says.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

See the article here:
New Insight as to How Cells Maintain Their Identity - Nature World News

Recommendation and review posted by Bethany Smith

Youll be glowing.

Skincare brand Andalou has introduced a new product line to its naturally-derived offering, citing hemp as a total skin saver.

The brand formulates its innovative products around fruit stem cell science, which utilises antioxidants that occur in apples, grapes and other natural ingredients.

For the new CannaCell range, stem cells are extracted from the stalk of hemp plants and included in each product along with organic hemp seed oil.

While the vitamin and protein-rich oil helps soothe distressed skin and boost water retention, the stem cells work to prevent oxidative damage, and counteract sun exposure and pollution.

Leading the pack for the new line is Andalous CannaCell Glow Mask. The exfoliating, botanical enzyme-based mask has a jelly-like consistency and warms the skin while it works its magic.

Then, after a relaxing 10-20 minutes, youll find your skin hydrated, soothed and glowing.

The CannaCell range is available online now.

@andalounaturals_au

See original here:
You can now use plant stem cells to rejuvenate your skin - Fashion Journal

Recommendation and review posted by Bethany Smith

The news that Formula One legend Michael Schumacher was moved to a hospital in Paris last week for pioneering stem cell therapy has provoked a fever of hope and speculation among fans that his condition could be improved.

After suffering devastating head injuries in a ski accident almost six years ago, Schumacher was placed in a coma for six months and has been receiving treatment at his home in Switzerland. He has not been seen in public since the accident.

His privacy is closely guarded and, while it is understood he cannot walk or stand, and, according to former Ferrari manager, Jean Todt, he may still have trouble communicating, nothing has been confirmed officially.

No wonder then that fans have been so excited to hear Schumacher is now under the care of world-renowned cardiac surgeon Philippe Menasch, described as a "pioneer in cell surgery" at the Georges-Pompidou hospital in Paris.

READ MORE:* Schumacher 'conscious' after treatment*Corinna Schumacher provides rare update*Schumacher 'struggles' to communicate*Mick Schumacher trying to emulate his dad

Stem cells are cells that can differentiate or change into other types of cell, opening the possibility of replacing damaged cells with healthy ones. Scientists have been looking into their use since the Sixties, most successfully so far in cases of cancers of the blood or bone marrow. More than 26,000 patients are treated with blood stem cells in Europe each year.

And since the Eighties, skin stem cells have been used to grow skin grafts for patients with life-threatening burns; most recently, a new stem cell-based treatment to repair damage to the cornea (the surface of the eye) after an injury like a chemical burn, has received conditional approval in Europe.

But their flexibility offers hope for lots of illnesses and conditions including heart disease, MS and macular degeneration and clinical trials are progressing in all these areas. Chronic spinal cord injury is being researched with some promise, thanks to the Christopher & Dana Reeve Foundation, set up after actor Christopher Reeve was paralysed in a riding accident.

Crucially, for cases such as Schumacher, stem cells are also being explored for neurodegenerative diseases like Parkinson's and Alzheimer's and traumatic brain injuries like the one he suffered in a skiing accident in December 2013.

Head injuries are difficult to treat as brain damage cannot be undone and each case is different. Asked for comment by The Daily Telegraph, the hospital responded that they could neither confirm nor deny the presence of Schumacher.

However, if he is under the care of Menasch, it is likely he will have had stem cells delivered by an IV to the area of the body where it is felt they could work best - whether that is his head or heart.

CHRISTOPHE ENA/AP

Paris' Georges-Pompidou Hospital, where Michael Schumacher is reportedly a patient.

In a recent interview online, Menasch explained that stem cell treatment for cardiac conditions - his particular area of expertise - is in its infancy. "Nobody really knows how stem cells are working," he said. "They do not permanently transplant into the myocardium [the muscular tissue of the heart] - after a couple of days or weeks, they just disappear.

"But you still may have a functional benefit as during their transient stay in the heart," he explains in the Future Tech podcast, "as the cells release molecules into the tissue. The hypothesis is that the repair comes from the heart itself, stimulated by these molecules."

Should the stem cells have been intended for Schumacher's brain injury, research suggests that the treatment has potential. A University of Plymouth study published in the journal Cell Reports in June found that neural stem cells could be used to "wake up" and produce new neurons (nerve cells) and surrounding glial cells in the brain.

The research is in its infancy, says lead author Dr Claudia Barros, from the Institute of Translational and Stratified Medicine at the University of Plymouth, who acknowledges there is still a long way to go until such findings can be translated into human treatments.

"We are working to expand our findings, to bring us closer to the day when human neural stem cells can be controlled and efficiently used to facilitate brain damage repair, or even prevent brain cancer growth that is fuelled by stem-like cells," she says.

A Chinese study published last month in the journal Frontiers in Cellular Neuroscience examined the current state of progress into the effects of stem cell therapy on traumatic brain injury. But the researchers from Zhejiang University, Hangzhou warned much more work was needed: "Although a large number of basic studies have confirmed that stem cells have good effect in the craniocerebral injury," they said, "the safety of stem cells, the route of injection, the time of injection and the specific mechanism are all factors that affect the clinical application of stem cells, and are the important research point in the future study."

PREMA TEAM

Mick Schumacher doesn't mind the comparisons with his seven-time F1 champion father Michael.

In the UK, some applications of stem cell medicine are already available privately, although tightly controlled by the Human Tissue Authority and not in the brain.

Simon Checkley, CEO at the Regenerative Clinic in Brighton, explains: "It is possible to get stem cells from sources outside your body, like the umbilical cord or Wharton's jelly [the vitreous humour in the eyeball], but in the UK we can only take stem cells from our own bodies.

"It is possible to get them donated, but it is safer to use your own."

In some countries, stem cells can then be manipulated in a laboratory but that is illegal in the UK, says Checkley. "There is a concern with cultured stem cells which have been bred in a Petri dish that they may keep proliferating after you transplant them into a body. That, having triggered their growth, you can't stop it and no one knows what might happen."

At the Regenerative Clinic, stem cells are taken from adipose fat, where they are plentiful, and then injected back into the area to be treated - mostly arthritic joints.

"We are seeing fantastic results," Checkley says, "with reduced pain and improved mobility for 80 per cent of patients." He is considering a clinical trial which could see the treatment pass through the National Institute for Health and Care Excellence (NICE) and become available on the NHS.

The therapy is still only four years old, he emphasises. "We have treated 1000 patients so far and around the world, it's about 40,000. We need longer-term studies."

LUCA BRUNO/AP

Michael Schumacher has not been seen in public since suffering a serious brain injury in a skiing accident nearly six years ago.

This type of stem cell treatment is also offered in the UK for post-menopause vaginal atrophy and stress incontinence, Checkley says, plus the genital skin condition lichen sclerosis. In all these cases, he says, the mechanism is the same: the stem cells are not replicating dead or dying cells but acting as signalling devices, alerting the body that this is an area where healing is needed.

For stem cells to work in more complex conditions, they would need to be manipulated, Checkley says. In cases of brain injury or disease, that would mean altering stem cells so that they could be targeted more precisely. But he believes the role would be similar: "The idea is they would go to the area of greatest damage and signal the body to regrow tissue there."

Cost would be a huge factor, he points out. A treatment for arthritis costs about 6000 (NZ$11,700) at the Regenerative Clinic but an IV-led treatment for brain injury with manipulated stem cells could cost up to 50,000 (NZ$98,000). But then what price recovery from a traumatic brain injury? Full recovery thanks to stem cells would be a prize beyond value.

See original here:
Reported stem cell treatment could give hope to Michael Schumacher - Stuff.co.nz

Recommendation and review posted by Bethany Smith

The legal and regulatory tools designed to protect the public from the marketing of unproven stem cell therapies will remain ineffective without bureaucratic will and grassroots efforts, according to a University of Alberta health law expert.

There's this perception that stem cells are revolutionizing science and they have transformed medicine already, but that's just not the case, said Timothy Caulfield.

You see the word stem cells being used to sell everything from skin cream to sports recovery tools to supplements, it's absolutely everywhere.

Caulfield, who refers to the marketing of spurious stem cell treatments as scienceploitation, explained there are actually only a handful of such therapies that have been approved for use in a clinical setting.

The most well known is probably the use of stem cells in bone marrow transplants and certain kinds of leukemiabut these therapies have been around for decades, he said, adding other stem cell therapies have shown some effectiveness in the treatment of bad burns and blindness.

But that's it.

In a paper outlining a strategy to combat the spread of misrepresentation within this field, Caulfield and Health Law Institute research associate Blake Murdoch argued the first step is to leverage the powers wielded by the provincial colleges of physicians and surgeons.

We need a more robust response from them because they have the power to stop their members from marketing treatments inappropriately and from offering services that are unproven, said Caulfield.

We haven't seen that, and it really is their role to protect the public.

He added organizations aimed at stopping the spread of misinformation and inaccurate marketinglike Ad Standards, Canadas advertising industry's non-profit self-regulating body, or Competition Bureau Canada, the federal advertising regulatorcan also be more involved.

While the Competition Bureau can only prohibit clinics from using misleading advertising and

not the provision of unproven interventions, this would help to stop the spread of misinformation, which may curtail public interest, said Caulfield.

He added political pressure on federal and provincial lawmakers could encourage change and allow a more comprehensive response, but noted that targeting the marketing of these treatments might be the more politically palatable course of action.

I think a really good logical first step is if you're going to market this stuff, if you're going to offer these services, the information you're using to market the services has to be accurate.

Even as the paper was being published, Caulfield said Health Canada weighed in by stating stem cell therapies need its approval.

Basically, if youre an MD, and you're providing stem cell therapy, you need to get it approved, said Caulfield. In the paper, we said Health Canada has got to get more aggressive, and thankfully, we're starting to see some action in that space.

He said ultimately, however, responses from Canadas regulatory bodies are often triggered by complaints from the public.

I've actually spoken to regulators, and theyre not hearing complaints about people being injured by stem cell treatment, said Caulfield. Of course, just because something is safe, doesn't mean it's a good idea.

Not only have some of these treatments shown to have caused real harm while offering little more than hope, Caulfield said there is a financial exploitation element, all of which can only leave a black mark on the science.

The spread of clinics marketing these interventions may, over the long term, damage public trust in legitimate regenerative technologies, thus adversely impacting their future development, he said. It confuses what is an incredibly promising field.

The most perplexing element of the proliferation of these treatments is the involvement of medical professionals who should know better, Caulfield said.

The team went into the analysis with the hypothesis that alternative practitioners were the ones providing and marketing stem cell therapies. This was true, but Caulfield said they were surprised to find that an MD was often involved.

I've been in the room with these health providers, and you get the sense that many of them believe it works.

More:
Regulatory heft needed to curb false promises on stem cells, says health law expert - Folio - University of Alberta

Recommendation and review posted by Bethany Smith

Scientists have developed a baseball cap that zaps your scalp and could reverse male balding.

Experts first created a wireless patch that can stimulate the scalp with electric pulses to encourage hair growth.

The 0.4-inch-thick plastic patch contains layers of differently charged materials that produce electricity when they come into contact and separate again.

Its a phenomenon known as the triboelectric effect and can result in faster hair re-growth than being hooked up to a machine for several hours a day. The team, from the University of Wisconsin-Madison, tested it out on the backs of shaved lab rats and found that when they moved it caused the flexible patch to bend and stretch.

They found that this movement activated the triboelectric effect and noted faster growth than in rats who had been given minoxidil lotion a common hair loss treatment.

Next the team, led by Xudong Wang, tested the patch on mice that were hairless because of a genetic deficiency.

They found that after nine days, 2-mm-long fur had grown on their skin under the patch compared with 0.8-inch-long hair that had grown on skin treated with minoxidil.

The density of the hair was also three times greater for the patch-treated areas.

Wang also tested the patch on his dad, who has been going bald for the past few years.

It helped him to grow a lot of new hairs after one month, he told New Scientist.

His team has now designed a baseball cap that encases the whole scalp in triboelectric materials.

Wang is seeking approval to test it in men in a clinical trial.

He says it shouldnt be uncomfortable to wear because it produces very gentle electric pulses.

However, the hat will only work in men who are currently losing their hair or have recently become bald, because the skin loses its ability to generate new hair follicles after many years of baldness, he added.

Its also unlikely to work as well when men sleep because they dont produce as many movements to power the device.

Small head movements during normal daily activity should be enough to power the device, he added.

Previously, we reported on a breakthrough treatment from a team of scientists who say they have used stem cells to develop a way of making unlimited hair.

In groundbreaking trials, human cells were grafted on to mice cells and attached to tiny scaffolds to help them grow straight.

They were then placed under the skin and emerged through it.

The team is now working toward tests on humans.

Around four in 10 Brit fellas suffer some form of baldness.

Read more here:
Cap that zaps your scalp could reverse male balding - New York Post

Recommendation and review posted by Bethany Smith

While manycelebrities swear that "tons of water and leafy greens" are the onlytwo factors behind an angelic red-carpet glow, Mandy Moore has alwaysbeen an open book with her fans, constantly documenting her friendship with herlongtime glam squad, the Streicher Sisters, and the work it takes to prep for abig event. Another piece of her glam squad she relies on, especially beforetomorrow's Emmy Awards? Her facialist.

In preparation fortomorrow's show, the This Is Us starwill be visiting her esthetician, Biba de Sousa, in Los Angeles for a specific"Red Carpet Skin Prep" treatment, complete with a very traditional,very interesting-looking facial that promises standout results. Below, the step-by-step from the skin expert herself.

You May Also Like:The 8 Beauty Products Mandy Moore Calls Her Favorites

Step one: For agentle, non-abrasive cleanse, de Sousa's soon-to-be-released micellar waterwill be used all over the skin, then she'll apply a "hydrating enzymaticmask to remove dead skin cells." Up next is lymphatic drainage of the faceand entire upper bodya must-try if you're looking to de-puff before a bigevent.

Now for the funstuff. Moore doesn't just get any old facialde Sousa incorporates a"DermaCulture system"with galvanic current, which she describes as one of the oldestaesthetic modalities (it got pushed aside by microcurrent machines). In fact,the machine is no longer manufactured"you have to wait until anesthetician retires in order to get their machine," she adds.

The time-testedtreatment consists of layers of gauze bandages soaked in a specificsolutionthink yucca root extract, magnesium sulfate, zinc sulfate and vitamin Capplied to the skin. Then, an old-timey galvanic mask is applied on top"to target tissue rejuvenation and firming via galvanic currents," deSousa explains. While definitely scary-looking (see below for proof from a brave beauty editor!), the results are said to be nothing short of incredible.

The finishing touch: a peptide-infused plant stem cell serum to keep skin looking dewybut we know what the real secret is.

Sign up to receive our newsletter

Excerpt from:
Mandy Moore Relies on a Galvanic Facial Before the Red Carpet - NewBeauty Magazine

Recommendation and review posted by Bethany Smith

HTF MI recently Announced Global Stem Cells study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Stem Cells. Global Stem Cells research allows you to get different methods for maximizing your profit. The research study provides estimates for Global Stem Cells Forecast till 2025*. Some of the Leading key Companys Covered for this Research are CCBC, Vcanbio, Boyalife & Beikebiotech.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market.

Click to get Global Stem Cells Market Research Sample PDF Copy Here @:https://www.htfmarketreport.com/sample-report/928542-global-stem-cells-market-3

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.The global Stem Cells market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.

Global Stem Cells Research for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customers understanding, needs and wants. Also, reveals how effectively a company can meet their requirements. The market research collects data about the customers, marketing strategy, competitors. The Stem Cells Manufacturing industry is becoming increasingly dynamic and innovative, with more number of private players entering the industry.

Important Features that are under offering & key highlights of the report:

1) Who are the Leading Key Company in Global Stem Cells market space?

Following are list of players that are currently profiled in the report CCBC, Vcanbio, Boyalife & Beikebiotech

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.2) What will the market size be in 2025 and what will the growth rate be?In 2019, the Global Stem Cells market size was xx million USD and it is expected to reach USD xx million by the end of 2025, with a CAGR of xx% during 2019-2025.

3) By What Applications & Types Does Market Study is Segmented:

The study is segmented by following Product Type: , Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell & Other

Major applications/end-users industry are: Diseases Therapy & Healthcare

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

To comprehend Global Stem Cells market dynamics in the world mainly, the worldwide Stem Cells market is analyzed across major regions. HTF MI also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/928542-global-stem-cells-market-3

Competitive Analysis:The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as CCBC, Vcanbio, Boyalife & Beikebiotech includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.Research Parameter/ Research Methodology

Primary Research:The primary sources involves the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Check for Discount, Offers ranging from 15% to 35% on Immediate Purchase on different Licenses @https://www.htfmarketreport.com/request-discount/928542-global-stem-cells-market-3

In this study, the years considered to estimate the market size of Global Stem Cells are as follows:History Year: 2013-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

Key Stakeholders in Global Stem Cells Market:Global Stem Cells ManufacturersGlobal Stem Cells Distributors/Traders/WholesalersGlobal Stem Cells Subcomponent ManufacturersIndustry AssociationDownstream Vendors

**Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Buy this research @https://www.htfmarketreport.com/buy-now?format=1&report=928542

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter|Google+

Link:
Stem Cells Market Will Generate New Growth Opportunities in the upcoming year - OnYourDesks

Recommendation and review posted by Bethany Smith

The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.

The global circulating tumor cells and cancer stem cells market is anticipated to grow at a rapid rate owing to development in biotechnology and biomedical engineering. According to WHO, Cancer is the leading cause of mortality and morbidity globally impacting about 14 million people annually, leading to rapid increase in research activities worldwide. Circulating tumor cells and cancer stem cells are under research for various types of cancer such as breast cancer, lung cancer, colorectal cancer, skin cancer. Government and various government bodies are taking interest and initiative to boost funds and activities which is one of the major factor driving the growth of the global circulating tumor cells and cancer stem cells market. Increase in demand of oncology screening, diagnosis and treatment monitoring the patients disease progression is one of the factor likely to propel the growth of the market through 2024. Furthermore, application of the circulating tumor cell for the drug discovery, use of cells in development of tumor specific biomarkers for targeted therapies are driving the growth of the global market. However, the ethical issues involved in research and regulation to perform human trials are some of the major factor that are retraining the growth of the global market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13306?source=atm

Based on technology type, the global circulating tumor cells and cancer stem cells market is divided into following Cell enrichment Detection CTC Analysis

Based on Application types, the global circulating tumor cells and cancer stem cells market is divided into following Biomarkers Tumorigenesis Stem cell research Others

The global circulating tumor cells and cancer stem cells market is segmented on the basis of technology type, application type and geographical region. On the basis of technology type the global market is divided into cell enrichment, Detection and CTC Analysis. Enrichment is further divided into positive selection, negative selection, Microchips and others. Detection is further divided into Immunocytochemicals technology, Molecular based technology, EPISPOT functional invitro assay. Cell Enrichment accounted for the largest market share globally owing to higher usage in oncology research and highly accurate technology. Microchip technology is expected to register high growth in the global market due to introduction of cluster chip technology which enables to capture the clusters of circulating tumor cells. On the basis of application type, the global market is divided into Biomarkers, tumorigenesis, stem cell research and others.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/13306?source=atm

Geographically the global circulating tumor cells and cancer stem cells market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is the dominating region in the global market attributing to the factors like developed economy, developed healthcare domain, strong funding for oncology research, rise in prevalence rate of cancer, favorable initiatives by government bodies. Asia Pacific region is expected to register high growth during the forecast period as a result of awareness, development of research and healthcare domains and prevalence of cancer.

Some of the major player operating in the global circulating tumor cells and cancer stem cells market are QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics, LLC, CellTraffix Inc., Silicon Biosystems, Advanced Cell Diagnostics, Inc. among others worldwide. To maintain a significant position in the global market key players are involved in collaboration with the cancer research universities and hospitals, for example in November 2015 Epic Sciences announced collaboration Abramson cancer Centre of University Pennsylvania. This collaboration is expected to explore the field of biomarkers which are identified by circulating tumor cells. The key participants are expanding the market by developing the facilities in different regions. For example, in September 2014 advanced cell diagnostic Inc. established a subsidiary in Europe to serve the European market.

The report covers exhaustive analysis on: Circulating Tumor Cells and Cancer Stem Cells Market Segments Circulating Tumor Cells and Cancer Stem Cells Market Dynamics Historical Actual Market Size, 2013 2015 Circulating Tumor Cells and Cancer Stem Cells Market Size & Forecast 2016 to 2024 Circulating Tumor Cells and Cancer Stem Cells Market Current Trends/Issues/Challenges Competition & Companies involved Circulating Tumor Cells and Cancer Stem Cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/13306?source=atm

The rest is here:
Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 - Commerce Gazette

Recommendation and review posted by Bethany Smith

Today in science fiction becoming science reality researchers grew a series of mini-brains in a laboratory. Yes, you read that correctly. Perhaps you might not be shocked at all. Researchers have already gone on to 3D print organs like skin,a functioning heart, and a functioning pair of lungs. However, todays event did not require the process of additive manufacturing, which begs the question What will we do with the brains we grow? So lets jump in a little further.

Now researchers did not only grow a brain in the laboratory, but the mini-brain was also able to generate human-like brain waves. Published in the August 29 issue of Cell Stem Cell, the aim of this project was to find new ways to study brain disorders.

However, when you think about it, the project does raise some very difficult questions about when consciousness begins and where this research is going, questions that are sure to keep your Ethics 101 class going for the semester.

Alysson Muotri, a neuroscientist at the University of California, San Diego, grew over 100 mini-brains in Petri dishes in his lab. For the uninitiated, these brains can also be described as organoids. Muotri plans to use his organoids to study neurological disorders, like autism or epilepsy. Now, these brains are not fully functioning conscious beings like us, though philosophers might argue otherwise.

Brain organoids have been already created but Muotris creation is special. As mentioned above, his brains are active, and have a functional human-like neural network, or a web of neurons that can transmit information across the brain.

RELATED:A COMPANY CREATES THE FIRST 3D PRINTED MINI HEART

Even though psychiatric conditions rarely make a physical appearance, you could even use these brains to study diseases like schizophrenia, bipolar disorder, or depression as these diseases affect how the neurons connect and send electrical impulses throughout the brain.

Now the brain organoids were about the size of a pea and were grown using human stem cells over a 10 month time period. The next step of Muotris brain experiment is using the mini-brains for autism research as well as launching a company to make the organoids for commercial use, such as testing new drugs.

This work really shows that organoid has complex patterns of neural activity for future studies. They allow us to study whether (the brain waves) are altered in different diseases. We normally did not have access to study, saidMuotri.

Read the rest here:
Researchers Grow Pea-Sized Brains in Laboratory That Produce Detectable Brain Waves - Interesting Engineering

Recommendation and review posted by Bethany Smith

Skin is the largest organ of the human body. It is composed of three layers: epidermis-the outermost layer; dermis-contains sweat glands, hair follicles and connective tissue and hypodermis-made up of fat and connective tissue. The main functions of the skin includes protection, sensation and regulation. The skin acts as a barrier and provides protection against harmful chemicals, radiation, microorganism and changing environmental conditions. It also helps regulate body temperature and maintain fluid balance. Skin is an extensive network of nerve cells and contains various receptors to detect changes in the environment such as touch, pain, heat and cold. Damage to skin due to burn or trauma can disrupt all the vital functions performed by the skin.

Currently, topical antibiotics, skin grafting, wound dressings and tissue-engineered substitutes are available in the market that are used to treat skin-related disorders. A skin graft can be done by natural substitute such as amniotic membrane, potato peel or artificial material that includes synthetic polymer sheet, polymer foam or spray. These substitute helps in the healing process. Skin regeneration refers to the regrowth of the damaged skin from the remaining tissue. Stem cell therapy has a vital application in skin regeneration.

Dermal regeneration matrix device provides an appropriate environment that is necessary for the proliferation and differentiation of skin cells. It helps in triggering the bodys own repair mechanism by cell signaling, that drive the matrix environment in wound healing process. Dermal regeneration matrix device is used to treat skin burns and is also finds application in reconstructive surgery for contractures (scars). The dermal regeneration matrix device is placed over the damaged skin which provides an environment for regeneration of new skin and tissue. The matrix is made of cow collagen, silicone and shark cartilage.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/12166?source=atm

In 1996, the U.S. Food and Drug Administration (FDA) first approved integra dermal regeneration matrix device for treatment of burn injuries. In 2002, dermal regeneration matrix device was approved for use in reconstructive surgery for burn scars. About 30 million people in the U.S. are suffering from diabetes, of which 15% experience a diabetic foot ulcer in their lifetime. In January 2016, FDA approved the use of dermal regeneration matrix for treatment of chronic diabetic foot ulcers (DFU). The usage of dermal regeneration matrix device is expected to expand the growth of dermal regeneration matrix device owing to increase usage in chronic foot ulcer.

Technological advancement and continued research in the development of artificial skin promises to bring more products to the marketplace. Increasing adoption of the device and long-term benefits associated with its application are some of the factors expected to fuel growth of the global dermal regeneration matrix device market over the forecast period. However, less awareness among the consumers and high cost of device are some of the key factors that could hamper growth of the market.

The global dermal regeneration matrix device is segmented on the basis of source, application, end user and geography. Segmentation by source Cow Collagen Silicone Shark Cartilage Segmentation by end user Hospitals Dermatology Centers Segmentation by application Burn Trauma Reconstructive Surgery Chronic Diabetic Foot Ulcers

On the basis of source, the global dermal regeneration matrix device market is segmented into cow collagen, silicone and shark cartilage. On the basis of end user, the global dermal regeneration matrix device market is segmented into hospitals and dermatology centers. The hospital segment is expected to contribute significantly to the total market in terms of market share. According to World Health Organization, over 265,000 deaths are caused due to burns each year. The majority of the burn cases occur in low and middle-income countries. Injuries such as traffic collisions, falls, burns, drowning, poisoning and others are expected to kills around five million people worldwide. Thus, the demand for dermal regeneration growth matrix is expected to be high in the low and middle-income countries over the forecast period.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/12166?source=atm

On the basis of region, the global dermal regeneration matrix device market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

Some of the major players in the global dermal regeneration matrix device market include Integra LifeSciences Corporation, Platelet BioGenesis, Avita Medical, Stratatech, Organogenesis Inc., Smith & Nephew, Inc., ACell Inc., Symatese and others.

The report covers exhaustive analysis on: Dermal Regeneration Matrix Market Segments Dermal Regeneration Matrix Market Dynamics Historical Actual Market Size, 20132015 Dermal Regeneration Matrix Market Size and Forecast, 20162024 Dermal Regeneration Matrix Market Current Trends/Issues/Challenges Competition and Companies Involved Dermal Regeneration Matrix Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting industry dynamics In-depth market segmentation Historical, current and projected industry size and recent industry trends Key competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/12166?source=atm

View original post here:
Dermal Regeneration Matrix Device Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2025 - The Market...

Recommendation and review posted by Bethany Smith

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/23101?source=atm

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography: Segmentation by Treatment Allogeneic Amniotic Fluid stem cell therapy Autologous Amniotic Fluid stem cell therapy Segmentation by Application Regenerative medicines Skin Orthopedics Oncology Fetal tissue reconstruction Kidney regeneration Regeneration of neural tissue Cardiac regeneration Lung epithelial regeneration Others Drug research and development Segmentation by End User Hospital Ambulatory Surgical Centers Specialty Clinics Academic and Research Institutes Segmentation by Geography North America Latin America Europe Asia-Pacific Excluding China China Middle East & Africa

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/23101?source=atm

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on: Amniotic Fluid Stem Cell Therapy Market Segments Amniotic Fluid Stem Cell Therapy Market Dynamics Historical Actual Market Size, 2012 2016 Amniotic Fluid Stem Cell Therapy Market Size & Forecast 2016 to 2024 Amniotic Fluid Stem Cell Therapy Market Current Trends/Issues/Challenges Competition & Companies involved Amniotic Fluid Stem Cell Therapy Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Excluding China China The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/23101?source=atm

Originally posted here:
Amniotic Fluid Stem Cell Therapy Market New Growth Opportunities By2018 2026 - Market Reporter

Recommendation and review posted by Bethany Smith

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors. These stem cell-derived cells are then developed using a complete culture system that is an easy-to-use system used for defined iPS-derived cell expansion. Majority of the key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

Browse Full Report at https://www.persistencemarketresearch.com/market-research/stem-cell-derived-cells-market

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type Stem Cell-Derived Cell Kits Stem Cell-Derived Definitive Endoderm Cell Kits Stem Cell-Derived Beta Cell Kits Stem Cell-Derived Hepatocytes Kits Stem Cell-Derived Cardiomyocytes Kits Accessories

Segmentation by End User Hospitals Research and Academic Institutions Biotechnology and Pharmaceutical Companies Contract Research Organizations/ Contract Manufacturing Organizations

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/28780?source=atm

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on: Stem cell-derived cells Market Segments Stem cell-derived cells Market Dynamics Historical Actual Market Size, 2014 2018 Stem cell-derived cells Market Size & Forecast 2019 to 2029 Stem cell-derived cells Market Current Trends/Issues/Challenges Competition & Companies involved Stem cell-derived cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Get Full Report Access of this report at https://www.persistencemarketresearch.com/checkout/28780?source=atm

Follow this link:
Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - NewsVarsity

Recommendation and review posted by Bethany Smith

Chef Avi Shemtov helps spread the word about BRCA gene mutations with a free dinner

SHARON Eliza Danielson and Jordana Phillips sat at a table for two, excitedly discussing the night's events. But instead of speculating about the chef's tasting menu they were about to be served, Phillips, a radiologist from New York City, was stressing the importance of BRCA mutation testing to Danielson.

I understand that, sometimes, testing for gene mutations can cause anxieties, but this is not one of those times, Phillips said. Danielson agreed to get tested, admitting that she hadnt known about the breast cancer mutation or how dangerous it could be.

Chef Avi Shemtov said this type of conversation is exactly why he held a free dinner last week at Simcha, a Sharon restaurant where Shemtov serves Israeli and Turkish cuisine with New England influences. On Thursday he hosted Nadine Tung, an oncologist specializing in breast cancer, to talk about an ongoing study that includes free genetic testing that helps men and women who are Ashkanazi Jews find out whether they have the mutation, which could significantly increase their chances of getting cancer.

Simcha was filled with predominantly women on Thursday night, with just one man accompanying his wife to the lecture in the packed restaurant. Tung said that she had expected as much because BRCA gene is an abbreviation for breast cancer gene, but that didn't mean that men couldn't be affected by it. A mutation in BRCA 1 raises a woman's chance of getting breast cancer to 87 percent and a mutation in BRCA 2 can cause an extremely aggressive and life-threatening type of prostate cancer in men.

Thursday's free meal at Simcha targeted the area's Jewish population because the mutation Tung is studying is most common among Ashkanazi Jews. Tung said Ashkanazi Jews have a one in 40 chance of having a mutation to the BRCA genes, which is 10 times higher than the general population. Sephardic Jews do not have a higher risk for mutation.

We all inherited some bad genes that put us at risk, said Tung, an Ashkanazi Jew herself. She said that she firmly believed in testing for genetic mutations, even if it can be scary. The information is something you can learn from and take preventative measures.

While Tung spoke, servers brought out plates of wood-oven baked pita and hummus, beets roasted in cast-iron skillets and topped with an Israeli blend of nuts and seeds, and confit chicken wings tossed in sweet and spicy paprika. The food is a reflection of Shemtovs culture, Sephardic food that has an emphasis on Israeli and Turkish cuisine. Shemtovs fathers family moved to Israel from Turkey to escape oppression. There, they met neighbors who had come from all over the world. This influenced Shemtovs grandparents cooking, and ultimately his father and his own cooking for their restaurants.

The major difference between Sephardic and Ashkanazi Jews is their cultural ancestry, Tung said. Sephardic Jews come initially from Spain and traveled to the Middle East and Israel from the Mediterranean Sea. Ashkanazi Jews are from Eastern Europe, Poland and Russia and make up approximately 95 percent of the Jewish population in America.

Shemtov said that even though he is a Sephardic Jew, he felt it was important to help spread information that could help the majority of the American Jewish population. To him, cancer screening is personal, though it is his mother, who converted to Judaism when she married his father, whose family has a greater history a history of cancer.

Shemtov said his mother's father died when she was 12, leaving behind several children. Since becoming a father, Shemtov said he felt he owed it to his children to be tested as frequently as possible for cancer, and he felt others owed it to their families to be tested, as well. When he was approached to host this event, he said he felt compelled to help. Shemtov said that, to him, this event and educating people about BRCA mutations is a way to help others.

If we can identify the gene (mutations) and we can detect cancer, why wouldnt I help spread the word? Shemtov said. He said it was important to him to not just use his restaurant and status as a chef to talk about food.

At one point in the night, Tung announced to the full restaurant that she hoped everyone would spread the word about the BRCA gene mutations to their friends, and also spread the word about how amazing Simchas food was. Shemtov laughed and told people to focus on the gene more, and less about the food.

Burgers, pita, pizza and falafel wont change the world, but it can give me a platform to help others, Shemtov said.

As Tung took questions from the audience, Shemtov leaned against the bar. He was smiling as he looked out at everyone talking. When asked what was on his mind, Shemtov took a second to look over at his mother and sister sitting at the bar before answering.

Whats one free dinner going to cost me if it ends up saving someones life? he said. "If one person out of everyone in this room finds out they have the mutation, then it's completely worth it."

Visit link:
Sharon chef stresses importance of genetic testing - The Patriot Ledger

Recommendation and review posted by Bethany Smith